Synthetic Biology Investor Summit
–
Industry conference. Imported as part of the seed dataset for the events listing layout review — replace with editorial copy when the real listing goes live.
Synthetic Biology Investor Summit
Spectral Medical PMX shows sustained mortality benefit at 12 months
GH Research publishes Phase 2a PPD data for inhaled GH001
Ona Therapeutics raises $86.6m Series B to bring ADCs into clinic
Gilead and Lakefront close Ouro Medicines deal for $1.675bn
ACTG launches Phase 2 trial of dasatinib to shrink HIV reservoir
Attralus wins FDA orphan drug status for AL amyloidosis candidate AT-02
Biogen's salanersen wins FDA Breakthrough Therapy tag for SMA
Novartis ALIGN data show Vanrafia slows IgAN kidney decline by 34%
Alpha Tau and Tolmar partner to commercialise Alpha DaRT in U.S.
Novartis Cosentyx Phase III PMR data published in NEJM
Iovance wins TGA approval for lifileucel in advanced melanoma
CG Oncology: cretostimogene combo shows high CR in NMIBC
Cardiff Oncology: onvansertib hits 72% ORR in RAS-mutated mCRC
Candel prostate therapy shows 30% DFS gain in Lancet Oncology
BeyondSpring plinabulin triple shows durable NSCLC benefit